The company also plans to roll out BioBactro in Venezuela, Peru, Ecuador, and Bolivia.
Probiotics supplier Chr. Hansen (Hoersholm, Denmark) has signed an agreement with one of the major pharmaceutical companies in Colombia, Laboratórios Synthesis, which will solely distribute a dietary supplement capsule developed by Chr. Hansen targeting women’s healthy vaginal flora.
The supplement will be sold under the brand name BioBactro. It has been approved by Colombia’s medical authority, the National Institute of Food and Drug Monitoring (INVIMA).
“Women all over the world rely on the effect and user-friendliness of this [probiotic/healthy flora] concept, and we are pleased to see it launched in Colombia as country no. 37,” said Christian Due Jensen, Chr. Hansen’s regional sales manager, human health and nutrition, in a press release.
“Our agreement with Laboratórios Synthesis is one of several new probiotic deals for Chr. Hansen in Latin America,” he continued. “Moving ahead, we are stepping up our activities in this bustling, emerging market, with the aim to become a key player in probiotics by actively offering our internationally recognized solutions to dietary supplements producers and pharmaceutical companies across the region.”
Luis Palacios, managing director for Laboratórios Synthesis, added, “Reliability is a key value for our company, and with Chr. Hansen we can rely on the best clinically documented probiotic strains for women’s health.” He says the company also plans to roll out BioBactro in Venezuela, Peru, Ecuador, and Bolivia.